These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 19775491)

  • 1. Long-term follow up after bony mastoid and epitympanic obliteration: radiological findings.
    Vercruysse JP; De Foer B; Somers T; Casselman J; Offeciers E
    J Laryngol Otol; 2010 Jan; 124(1):37-43. PubMed ID: 19775491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of high-resolution computed tomography and magnetic resonance imaging in the detection of residual cholesteatomas in primary bony obliterated mastoids.
    De Foer B; Vercruysse JP; Pouillon M; Somers T; Casselman JW; Offeciers E
    Am J Otolaryngol; 2007; 28(4):230-4. PubMed ID: 17606036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioactive glass granules for mastoid and epitympanic surgical obliteration: CT and MRI appearance.
    Bernardeschi D; Law-Ye B; Bielle F; Hochet B; Sterkers O; Dormont D; Pyatigorskaya N
    Eur Radiol; 2019 Oct; 29(10):5617-5626. PubMed ID: 30888487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Results of Troublesome CWD Cavity Reconstruction by Mastoid and Epitympanic Bony Obliteration (CWR-BOT) in Adults.
    Vercruysse JP; van Dinther JJ; De Foer B; Casselman J; Somers T; Zarowski A; Cremers CC; Offeciers E
    Otol Neurotol; 2016 Jul; 37(6):698-703. PubMed ID: 27023012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerance and safety of 45S5 bioactive glass used in obliteration procedures during middle ear surgery: Preliminary results.
    Al Tamami N; Bawazeer N; Fieux M; Zaouche S; Tringali S
    Am J Otolaryngol; 2020; 41(6):102542. PubMed ID: 32620365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mastoid and epitympanic bony obliteration in pediatric cholesteatoma.
    Vercruysse JP; De Foer B; Somers T; Casselman JW; Offeciers E
    Otol Neurotol; 2008 Oct; 29(7):953-60. PubMed ID: 18719515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of mastoid obliteration techniques in cholesteatoma.
    Yung M; Bennett A
    Curr Opin Otolaryngol Head Neck Surg; 2013 Oct; 21(5):455-60. PubMed ID: 23872728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canal wall up surgery with mastoid and epitympanic obliteration in acquired cholesteatoma.
    Hellingman CA; Geerse S; de Wolf MJF; Ebbens FA; van Spronsen E
    Laryngoscope; 2019 Apr; 129(4):981-985. PubMed ID: 30408197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A technique for concurrent procedure of mastoid obliteration and meatoplasty after canal wall down mastoidectomy.
    Kim CW; Oh JI; Choi KY; Park SM; Park MI
    Auris Nasus Larynx; 2012 Dec; 39(6):557-61. PubMed ID: 22321811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of postoperative residual cholesteatoma with non-echo-planar diffusion-weighted magnetic resonance imaging.
    De Foer B; Vercruysse JP; Bernaerts A; Deckers F; Pouillon M; Somers T; Casselman J; Offeciers E
    Otol Neurotol; 2008 Jun; 29(4):513-7. PubMed ID: 18520587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial mastoid obliteration combined with soft-wall reconstruction for middle ear cholesteatoma.
    Suzuki H; Ikezaki S; Imazato K; Koizumi H; Ohbuchi T; Hohchi N; Hashida K
    Ann Otol Rhinol Laryngol; 2014 Aug; 123(8):571-5. PubMed ID: 24634153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-EPI DW MRI in planning the surgical approach to primary and recurrent cholesteatoma.
    Migirov L; Wolf M; Greenberg G; Eyal A
    Otol Neurotol; 2014 Jan; 35(1):121-5. PubMed ID: 24317217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mastoid and epitympanic obliteration in canal wall up mastoidectomy for prevention of retraction pocket.
    Lee WS; Choi JY; Song MH; Son EJ; Jung SH; Kim SH
    Otol Neurotol; 2005 Nov; 26(6):1107-11. PubMed ID: 16272924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recidivous cholesteatoma: DWI MR after canal wall up and canal wall down mastoidectomy.
    Bakaj T; Zbrozkova LB; Salzman R; Tedla M; Starek I
    Bratisl Lek Listy; 2016; 117(9):515-520. PubMed ID: 27677195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful obliteration of troublesome and chronically draining cavities.
    Geerse S; Ebbens FA; de Wolf MJ; van Spronsen E
    J Laryngol Otol; 2017 Feb; 131(2):138-143. PubMed ID: 28069077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canal-wall up cholesteatoma surgery with mastoid obliteration leads to lower rates of disease recurrence without affecting hearing outcomes.
    Erfurt C; Westerhout SF; Straatman LV; Smit AL; Stokroos RJ; Thomeer HGXM
    Front Surg; 2024; 11():1381481. PubMed ID: 38650663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative diffusion weighted MRI and preoperative CT scan fusion for residual cholesteatoma localization.
    Alzahrani M; Alhazmi R; Bélair M; Saliba I
    Int J Pediatr Otorhinolaryngol; 2016 Nov; 90():259-263. PubMed ID: 27729145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cholesteatoma: status of the canal wall.
    Syms MJ; Luxford WM
    Laryngoscope; 2003 Mar; 113(3):443-8. PubMed ID: 12616194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiological Follow-up After the Bony Obliteration Tympanoplasty in Detecting Residual Cholesteatoma: Towards an Optimal Postoperative MR Imaging Protocol.
    van der Toom HFE; van Dinther JJS; Zarowski A; Baazil AHA; De Foer B; Bernaerts A; Casselman JW; Offeciers E
    Otol Neurotol; 2022 Jan; 43(1):e79-e87. PubMed ID: 34607996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary experience with beta-tricalcium phosphate for use in mastoid cavity obliteration after mastoidectomy.
    Minoda R; Hayashida M; Masuda M; Yumoto E
    Otol Neurotol; 2007 Dec; 28(8):1018-21. PubMed ID: 17898672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.